Do Not Forget Poly (Adenosine Diphosphate-Ribose) Polymerase Inhibitors in Ovarian Carcinosarcoma.

Cureus

Oncology, Instituto Português de Oncologia Francisco Gentil Porto, Porto, PRT.

Published: July 2022

Ovarian carcinosarcoma (OCS) is a rare entity with a poor prognosis and without evidence-based therapy. Here, we report the case of a 55-year-old woman with a germline mutation and a stage IV OCS who was proposed olaparib maintenance therapy after three platinum-based chemotherapies in relapsed disease. Currently, the patient has an overall survival of 102 months and progression-free survival of 60 months with olaparib, with a good quality of life and not experiencing any adverse events. Despite the lack of evidence for the use of poly (adenosine diphosphate-ribose) polymerase inhibitors in OCS, our case report proves that patients with a potential biomarker of response to these drugs (such as mutation and platinum-sensitive disease) derive great benefits from it.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357426PMC
http://dx.doi.org/10.7759/cureus.26662DOI Listing

Publication Analysis

Top Keywords

poly adenosine
8
adenosine diphosphate-ribose
8
diphosphate-ribose polymerase
8
polymerase inhibitors
8
ovarian carcinosarcoma
8
forget poly
4
inhibitors ovarian
4
carcinosarcoma ovarian
4
carcinosarcoma ocs
4
ocs rare
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!